Article

Successful transduction of nonhuman primate trabecular meshworkwith lentiviral vectors reported

Investigators have successfully transferred lentiviral vectors, atype of retroviral vector, into the trabecular meshwork ofcynomolgus monkeys and achieved sustained transgene expression.

Investigators have successfully transferred lentiviral vectors, a type of retroviral vector, into the trabecular meshwork of cynomolgus monkeys and achieved sustained transgene expression.

"Because these vectors integrate permanently into the host genome, they are suitable for chronic diseases such as glaucoma," said Eric Poeschla, MD, of the Mayo Clinic College of Medicine, Rochester, MN.

He and his colleagues conducted a study in which five monkeys received transcorneal anterior chamber bolus injections of vesicular stomatitis virus glycoprotein G-pseudotyped, eGFP-encoding FIV vectors. The virus is not transferred, only the proteins, he explained. Single doses were administered; the doses used were 0.03 × 10-6, 0.3 × 10-7, and 1, and 2 × 10-8 transducing units, according to Dr. Poeschla.

The eyes injected with 1 and 2 × 10-8 transducing units had significant eGFP fluorescence in the trabecular meshwork about 1 month after injection. The 0.03 × 10-6 transducing units did not show fluorescence that was detectable by gonioscopy, and the eyes that received 0.3 × 10-7 transducing units had a low level of fluorescence. There was a mild-to-moderate inflammatory response in the eyes that received the highest dose, but that all but resolved after several weeks.

Interestingly, in the eyes that received the lower doses, in which no fluorescence was detectable by gonioscopy, the gene expression was apparent after the eyes were enucleated. The animals were followed for from 1 month to about 14 months.

"Sustained high-grade eGFP expression can be obtained in the trabecular meshwork of cynomolgus monkeys without raising the IOP and caused only short-term modest inflammatory," Dr. Poeschla said. "The clinical examination discloses only the highest levels of fluorescence and, therefore, underestimates the efficacy of gene transfer. The goal is to develop therapeutic transgenes for glaucoma."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.